Azenta, Inc. (NASDAQ:AZTA) Receives Consensus Rating of “Hold” from Analysts

Azenta, Inc. (NASDAQ:AZTA) has been given a consensus recommendation of “Hold” by the six analysts that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $69.60.

Several analysts have issued reports on the stock. Stephens restated an “equal weight” rating and set a $70.00 price objective on shares of Azenta in a research report on Thursday, February 8th. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of Azenta in a research report on Monday, April 8th. Evercore ISI lowered their price objective on shares of Azenta from $64.00 to $60.00 and set an “in-line” rating on the stock in a research report on Thursday, April 4th. Jefferies Financial Group assumed coverage on shares of Azenta in a research report on Thursday, April 4th. They set a “hold” rating and a $64.00 price target for the company. Finally, B. Riley lifted their price objective on Azenta from $61.00 to $79.00 and gave the stock a “buy” rating in a report on Thursday, February 1st.

Azenta Price Performance

NASDAQ:AZTA opened at $55.35 on Tuesday. The firm has a 50-day moving average of $58.11 and a 200-day moving average of $59.22. The company has a market cap of $3.09 billion, a PE ratio of -178.54 and a beta of 1.51. Azenta has a one year low of $36.01 and a one year high of $69.16.

Azenta (NASDAQ:AZTA) last released its quarterly earnings results on Wednesday, February 7th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $154.32 million for the quarter, compared to analysts’ expectations of $151.86 million. Azenta had a negative net margin of 2.92% and a positive return on equity of 0.49%. On average, equities research analysts expect that Azenta will post 0.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Azenta

A number of hedge funds have recently modified their holdings of the company. Federated Hermes Inc. lifted its holdings in shares of Azenta by 29.2% in the fourth quarter. Federated Hermes Inc. now owns 365,506 shares of the company’s stock worth $23,809,000 after buying an additional 82,502 shares in the last quarter. Citigroup Inc. raised its stake in Azenta by 558.8% during the third quarter. Citigroup Inc. now owns 88,078 shares of the company’s stock valued at $4,421,000 after purchasing an additional 74,708 shares in the last quarter. Millrace Asset Group Inc. purchased a new stake in Azenta during the third quarter valued at $1,074,000. Trexquant Investment LP purchased a new stake in Azenta during the third quarter valued at $860,000. Finally, Invesco Ltd. raised its stake in Azenta by 35.4% during the third quarter. Invesco Ltd. now owns 331,012 shares of the company’s stock valued at $16,613,000 after purchasing an additional 86,477 shares in the last quarter. 99.08% of the stock is currently owned by institutional investors.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.